Interplay between COVID-19 and Secukinumab treatment in Spondylarthritis patients during the omicron surge: a retrospective cohort study

References

• WHO. Pneumonia of unknown cause-China Disease Outbreak News. https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-causechina/en/
   Google Scholar
• WHO. Virtual press conference on COVI-19- 11. 2020.
   Google Scholar
• Akiyama S, Hamdeh S, Micic D, et al. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2021;80(3):1–7.
   Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034.
   PubMed Web of Science ®Google Scholar
• Pacha O, Sallman MA, Evans SE. COVID-19: a case for inhibiting IL-17? Nat Rev Immunol. 2020;20(6):345–346.
   PubMed Web of Science ®Google Scholar
• Muir R, Osbourn M, Dubois AV, et al. Innate lymphoid cells are the predominant source of IL-17A during the early pathogenesis of acute respiratory distress syndrome. Am J Respir Crit Care Med. 2016;193(4):407–416.
   PubMed Web of Science ®Google Scholar
• Pavelka K, Kivitz A, Dokoupilova E, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017;19(1):285.
   PubMed Web of Science ®Google Scholar
• Yin Y, Wang M, Liu M, et al. Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Res Ther. 2020;22(1):111.
   PubMed Web of Science ®Google Scholar
• Erichsen CY, Jensen P, Kofoed K. Biologic therapies targeting the interleukin (IL)-23/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2020;34(1):30–38.
   PubMed Web of Science ®Google Scholar
• Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373(26):2534–2548.
   PubMed Web of Science ®Google Scholar
• Behrens F, Sewerin P, de Miguel E, et al. Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the achilles tendon: results from a phase 3b trial. Rheumatology (Oxford). 2022;61(7):2856–2866.
   PubMed Web of Science ®Google Scholar
• Sieper J, Rudwaleit M, Baraliakos X, et al. The assessment of SpondyloArthritis international society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(Suppl 2):ii1–44.
   PubMed Web of Science ®Google Scholar
• National Health Commission & National Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for COVID-19 (trial version 9). 2022.
   Google Scholar
• Belleudi V, Rosa AC, Poggi FR, et al. Direct and indirect impact of COVID-19 for patients with Immune-Mediated inflammatory diseases: a retrospective cohort study. J Clin Med. 2021;10(11):2388.
   PubMed Web of Science ®Google Scholar
• Haberman RH, Castillo R, Chen A, et al. COVID-19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and Disease-Modifying antirheumatic drugs on clinical outcomes. Arthritis Rheumatol. 2020;72(12):1981–1989.
   PubMed Web of Science ®Google Scholar
• Rosenbaum JT, Weisman MH, Hamilton H, et al. The interplay between COVID-19 and spondyloarthritis or its treatment. J Rheumatol. 2022;49(2):225–229.
   PubMed Web of Science ®Google Scholar
• Raiker R, Pakhchanian H, Kavadichanda C, et al. Axial spondyloarthritis may protect against poor outcomes in COVID-19: propensity score matched analysis of 9766 patients from a nationwide multi-centric research network. Clin Rheumatol. 2022;41(3):721–730.
   PubMed Web of Science ®Google Scholar
• CDCP. COVID-19 vaccination guidelines. http://www.nhc.gov.cn/jkj/s3582/202103/c2febfd04fc5498f916b1be080905771.shtml
   Google Scholar
• Di Lernia V, Bombonato C, Motolese A. COVID-19 in an elderly patient treated with secukinumab. Dermatol Ther. 2020;33:e13580.
   PubMed Web of Science ®Google Scholar
• Balestri R, Rech G, Girardelli CR. SARS-CoV-2 infection in a psoriatic patient treated with IL-17 inhibitor. J Eur Acad Dermatol Venereol. 2020;34(8):e357–e8.
   PubMed Web of Science ®Google Scholar
• Li Q, Gu Y, Tu Q, et al. Blockade of interleukin-17 restrains the development of acute lung injury. Scand J Immunol. 2016;83(3):203–211.
   PubMed Web of Science ®Google Scholar
• Mugheddu C, Sanna S, Atzori L, et al. Safety of secukinumab treatment in COVID-19 affected psoriatic patients. Dermatol Ther. 2021;34:e14710.
   PubMed Web of Science ®Google Scholar
• Kivitz AJ, Wagner U, Dokoupilova E, et al. Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study. Rheumatol Ther. 2018;5(2):447–462.
   PubMed Web of Science ®Google Scholar
• Kishimoto M, Taniguchi A, Fujishige A, et al. Efficacy and safety of secukinumab in japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J). Mod Rheumatol. 2020;30(1):132–140.
   PubMed Web of Science ®Google Scholar
• Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19–34.
   PubMed Web of Science ®Google Scholar
• Escalas C, Trijau S, Dougados M. Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis. Rheumatology (Oxford, England). 2010;49(7):1317–1325.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Kiltz U, Kononenko I, et al. Treatment overview of axial spondyloarthritis in 2023. Best Pract Res Clin Rheumatol. 2023:101858.
   PubMedGoogle Scholar
• Goh L, Suresh P, Gafoor A, et al. Disease activity in longstanding ankylosing spondylitis: a correlation of clinical and magnetic resonance imaging findings. Clin Rheumatol. 2008;27(4):449–455.
   PubMed Web of Science ®Google Scholar
• Sieper J. Management of ankylosing spondylitis/axial spondyloarthritis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. Philadelphia: Mosby; 2015. pp. 970–985.
   Google Scholar